Corcept Faces Class Action Lawsuit After 50.4% Stock Price Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy CORT?
Source: Globenewswire
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Corcept on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025, with a deadline of April 21, 2026, for lead plaintiff applications.
- FDA Concerns Raised: The complaint alleges that Corcept's New Drug Application (NDA) faced scrutiny from the FDA due to inadequate clinical evidence, contradicting the company's claims of strong support from clinical trials.
- Stock Price Plummet: Following the announcement of a Complete Response Letter (CRL) from the FDA on December 31, 2025, Corcept's stock price fell dramatically from $70.20 to $34.80, marking a 50.4% decline and resulting in significant losses for investors.
- Legal Consultation Encouraged: The law firm is urging affected investors to reach out for legal rights discussions and potential claims, highlighting the firm's commitment to protecting investor interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 42.490
Low
50.00
Averages
91.00
High
121.00
Current: 42.490
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to represent other investors in the class action lawsuit.
- No Out-of-Pocket Fees: Investors participating in the class action may receive compensation without any upfront costs through a contingency fee arrangement, which lowers the financial barrier for more investors to join the lawsuit.
- FDA Approval Risks: The lawsuit claims that throughout the class period, Corcept misrepresented the strength of clinical trials supporting its drug relacorilant for hypercortisolism treatment, while the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Choosing Counsel: Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record, noting that many firms issuing notices lack the necessary experience in handling securities class actions, urging investors to be cautious in their choices to ensure their rights are effectively protected.
See More
UnitedHealthcare Shares Climb 9%, Humana Up 11% in After-Hours Trading After CMS Medicare Announcement
Healthcare Shares Rise: Shares of UnitedHealth Care increased by 9% following the announcement from CMS regarding Medicare.
Humana Gains: Humana's shares saw an 11% rise in after-hours trading, reflecting positive market reactions to the same CMS announcement.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of securities laws during the period from October 31, 2024, to December 30, 2025, with a deadline to contact the firm by April 21, 2026, to participate.
- False Statements: The complaint alleges that Corcept made false and misleading statements regarding its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate for approval, resulting in investor losses.
- Loss Recovery: Investors suffered damages when the truth about Corcept was revealed, and the Schall Law Firm specializes in securities class action lawsuits, aiming to assist affected shareholders in recovering their losses, highlighting the importance of legal recourse.
- Legal Process: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will remain absent class members, urging investors to act promptly to protect their rights.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to apply for Lead Plaintiff is April 21, 2026, urging investors who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegations: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose FDA concerns regarding the efficacy data of its lead drug candidate, relacorilant, misleading investors about the drug's prospects.
- Market Crash Impact: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, highlighting the significant impact of information asymmetry on the market.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further advancing the investigation into Corcept.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should be aware of the April 21, 2026, lead plaintiff deadline to participate in the class action.
- Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the NDA for relacorilant, concealing FDA concerns about clinical evidence, which led to investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record, prompting investors to carefully select experienced legal counsel.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: In the case of Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., plaintiffs allege that Corcept made materially false and misleading statements between October 31, 2024, and December 30, 2025, impacting investor decisions.
- Drug Candidate Issues: The lawsuit claims that Corcept failed to disclose critical information regarding its lead drug candidate, Relacorilant, resulting in investor losses due to an information gap between the company and the FDA.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further aiding the investigation into Corcept.
See More
Corcept Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to represent other investors in the class action lawsuit.
- No Out-of-Pocket Fees: Investors participating in the class action may receive compensation without any upfront costs through a contingency fee arrangement, which lowers the financial barrier for more investors to join the lawsuit.
- FDA Approval Risks: The lawsuit claims that throughout the class period, Corcept misrepresented the strength of clinical trials supporting its drug relacorilant for hypercortisolism treatment, while the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Choosing Counsel: Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record, noting that many firms issuing notices lack the necessary experience in handling securities class actions, urging investors to be cautious in their choices to ensure their rights are effectively protected.
See More
UnitedHealthcare Shares Climb 9%, Humana Up 11% in After-Hours Trading After CMS Medicare Announcement
Healthcare Shares Rise: Shares of UnitedHealth Care increased by 9% following the announcement from CMS regarding Medicare.
Humana Gains: Humana's shares saw an 11% rise in after-hours trading, reflecting positive market reactions to the same CMS announcement.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of securities laws during the period from October 31, 2024, to December 30, 2025, with a deadline to contact the firm by April 21, 2026, to participate.
- False Statements: The complaint alleges that Corcept made false and misleading statements regarding its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate for approval, resulting in investor losses.
- Loss Recovery: Investors suffered damages when the truth about Corcept was revealed, and the Schall Law Firm specializes in securities class action lawsuits, aiming to assist affected shareholders in recovering their losses, highlighting the importance of legal recourse.
- Legal Process: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will remain absent class members, urging investors to act promptly to protect their rights.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to apply for Lead Plaintiff is April 21, 2026, urging investors who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegations: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose FDA concerns regarding the efficacy data of its lead drug candidate, relacorilant, misleading investors about the drug's prospects.
- Market Crash Impact: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, highlighting the significant impact of information asymmetry on the market.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further advancing the investigation into Corcept.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should be aware of the April 21, 2026, lead plaintiff deadline to participate in the class action.
- Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the NDA for relacorilant, concealing FDA concerns about clinical evidence, which led to investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record, prompting investors to carefully select experienced legal counsel.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: In the case of Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., plaintiffs allege that Corcept made materially false and misleading statements between October 31, 2024, and December 30, 2025, impacting investor decisions.
- Drug Candidate Issues: The lawsuit claims that Corcept failed to disclose critical information regarding its lead drug candidate, Relacorilant, resulting in investor losses due to an information gap between the company and the FDA.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further aiding the investigation into Corcept.
See More
